A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of ABBV-932 in Healthy Adult Participants, Participants With Generalized Anxiety Disorder (GAD) and Participants With Bipolar Disorder (BPD)
← catalyst calendarSponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
72actual
Sites
3
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-08-31 | actual | When the study began enrolling |
| Primary completion | 2025-03-04 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-03-04 | actual | The whole study's end, after follow-up |
| First posted | 2023-09-06 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-03-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Healthy Volunteers
- Generalized Anxiety Disorder (GAD)
- Bipolar Disorder (BPD)
Interventions
- Drug: ABBV-932
- Drug: Placebo for ABBV-932
Primary outcomes
what the primary-completion date above is the date OFMaximum Observed Plasma Concentration (Cmax)
measured Up to Day 28
Time to Cmax (Tmax)
measured Up to Day 28
Plasma Concentrations at Pre-dose or at the End of a Dosing Interval (Ctrough)
measured Up to Day 28
Area under the Plasma Concentration-time Curve from Time Zero to the End of the Dosing Interval (AUCtau)
measured Up to Day 28
Number of Participants with Adverse Events (AEs)
measured Baseline to Day 129
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed